Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlanbia Regulatory News (GLB)

Share Price Information for Glanbia (GLB)

Share Price is delayed by 15 minutes
Get Live Data
21.20    0.00 (0.00%)
Bid:
21.20
Ask:
22.00
Spread: 0.80 (3.774%)
Market Cap: €5.12b
GLB Live PriceLast checked at - London Stock Exchange

Intraday Glanbia Share Chart

Statement on Equity Placement

30 Sep 2025 16:48

RNS Number : 4774B
Glanbia PLC
30 September 2025
 

Glanbia plc

Statement on Equity Placement 

Glanbia plc, the Better Nutrition company ("Glanbia" or "the Company"), has been informed by Tirlán Co-operative Society Limited ("Tirlán") that it intends to sell up to 17,000,000 ordinary shares (the "Equity Placement Shares") in Glanbia in order to finance the concurrent repurchase of Tirlán's outstanding €250 million 1.875 per cent Secured Exchangeable Bonds, due 27 January 2027 (ISIN: XS2436579978). The Equity Placement Shares represent approximately 7% of Glanbia's share capital.

The Equity Placement Shares are being offered to institutional investors by way of an accelerated bookbuild offering (the "Equity Placement"). Goodbody Stockbrokers UC ("Goodbody") and J&E Davy ("Davy") are acting as joint global coordinators and joint bookrunners in connection with the Equity Placement (Goodbody and Davy together the "Joint Global Coordinators"). Coöperatieve Rabobank U.A. in cooperation with Kepler Cheuvreux S.A. ("Rabobank-Kepler Cheuvreux") will act as joint bookrunner in connection with the Equity Placement (together with Goodbody and Davy, the "Joint Bookrunners").

Glanbia plc confirms it intends to participate in the Equity Placement by purchasing up to 45% of the Equity Placement Shares, subject to a maximum value of €100 million (the "plc Participation Amount"). Any shares purchased by the Company through this placement will be cancelled. The Board has approved a €50 million share buyback, additional to the €100 million authorised in February this year, to cover the plc Participation Amount.[1]

Glanbia has entered into an agreement with Davy to act as principal in relation to the purchase of the Company's Shares from the Equity Placement, within certain pre-set parameters. This share buyback programme may be conducted by way of block trades in accordance with the Company's general authority to repurchase shares. The Company confirms that it currently has no unpublished inside information.

Glanbia's participation in the Equity Placement will be conducted within the limitations of the Company's general authority to repurchase shares as set out in Resolution 10 approved by the Company's shareholders at the 2025 Annual General Meeting on 30 April 2025 and up to a maximum of 10% of the issued share capital of the Company (being 25,634,283 ordinary shares which has been reduced to 21,245,761 ordinary shares following the completion of the latest buyback programme). Unless renewed, this authority will expire on the earlier of the close of business on the date on which the next Annual General Meeting of the Company is held in 2026 (expected to be in April 2026) or 31 July 2026.

Further details Glanbia's participation in the Equity Placement, including the value of the plc Participation Amount, will be published once the transaction has completed.

ENDS

 

For further information contact:

Glanbia plc +353 56 777 2200

Mark Garvey, Chief Financial Officer

Liam Hennigan, Group Secretary & Head of Investor Relations: +353 86 046 8375

Martha Kavanagh, Director of Corporate Affairs: +353 87 646 2006

Davy

Ivan Murphy +353 1 679 7788

 

 


[1] In February 2025, Glanbia announced that its Board had approved a €100 million buyback authorisation. On 22 September Glanbia completed a €50 million share buyback programme under this authority.  On 30 September 2025 the Board approved increasing this buyback authorisation by €50 million to fulfil Glanbia's participation in the Equity Placement.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCLMMATMTIJBIA
Date   Source Headline
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 20261:26 pmRNSDirector/PDMR Shareholding
26th Mar 20267:00 amRNSTransaction in Own Shares
25th Mar 202612:06 pmRNSPublication of Notice of AGM & Proxy Voting Form
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 20267:00 amRNSTransaction in Own Shares
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20261:53 pmRNSAnnual Financial Report
11th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 202611:58 amRNSDirector/PDMR Shareholding
2nd Mar 20268:44 amRNSTotal Voting Rights
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSDividend Payment Date
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20267:30 amRNSGlanbia launches share buyback
25th Feb 20267:00 amRNSGlanbia Full Year 2025 Results
16th Dec 20252:08 pmRNSPublication of AGM Date
12th Dec 202511:13 amRNSDirector/PDMR Shareholding
11th Dec 20255:24 pmRNSCommittee Changes
19th Nov 20257:00 amRNSGlanbia CMD and New Medium-Term Targets
5th Nov 20257:00 amRNSThird Quarter Interim Management Statement
31st Oct 20258:45 amRNSTotal Voting Rights
20th Oct 202510:30 amRNSSale of SlimFast UK
3rd Oct 20253:45 pmRNSHolding(s) in Company
1st Oct 20257:30 amRNSTransaction in Own Shares
1st Oct 20257:03 amRNSRESULT OF SECONDARY SHARE SALE
30th Sep 20254:48 pmRNSStatement on Equity Placement
30th Sep 20254:43 pmRNSPROPOSED SECONDARY PLACING & TENDER OFFER
30th Sep 20258:27 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.